ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – www.careers.regeneron


 Key Statistics


Email:
Ownership: Public

Web Site: Regeneron Pharmaceuticals, Inc.
Employees: 2300+
Symbol: REGN
 



Industry
Biotechnology


Collaborations

Sanofi US 

Bayer Corporation 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotechnologies 





 Company News
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Bags BioMarin Pharmaceutical Inc. (BMRN)'s Special FDA Priority Review Voucher For $67.5 Million 7/30/2014 3:51:46 PM
FDA Release: EYLEA® (aflibercept) Injection Receives FDA Approval For The Treatment Of Diabetic Macular Edema (DME) 7/30/2014 7:57:29 AM
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Alirocumab Cuts Cholesterol In Nine Late-Stage Trials 7/30/2014 6:20:57 AM
Regeneron Pharmaceuticals, Inc. (REGN) To Report Second Quarter 2014 Financial And Operating Results And Host Conference Call And Webcast On August 5, 2014 7/21/2014 12:54:44 PM
Regeneron Pharmaceuticals, Inc. (REGN) Release: Two-Year Results From Phase 3 VIVID-DME Trial Of EYLEA® (aflibercept) Injection For The Treatment Of Diabetic Macular Edema Show Sustained Improvement In Vision 7/18/2014 9:20:28 AM
Technology, Smart Decisions: The Heart Of Regeneron Pharmaceuticals, Inc. (REGN)'s Remarkable R&D Productivity 7/15/2014 7:09:52 AM
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Tames Eczema In Phase 2b Trial 7/10/2014 7:44:48 AM
Sanofi (France) (SAN.PA) Raises Stake In Regeneron Pharmaceuticals, Inc. (REGN) 7/2/2014 6:54:28 AM
Regeneron Pharmaceuticals, Inc. (REGN)'s Injection Eylea Recommended For Approval By CHMP 6/27/2014 6:04:47 AM
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Tout Positive Phase 3 Data For Rheumatoid Drug Sarilumab 6/12/2014 5:43:58 AM
12345678910...